BioInsights - Venture creation for cell and gene therapy and beyond

Venture creation for cell and gene therapy and beyond

Cell & Gene Therapy Insights 2020; 6(3), 367–372


Published: 4 April 2020
Bruce Booth

BRUCE BOOTH is a partner at Atlas Venture and focuses on the discovery and development of novel medicines and therapeutic platforms. Bruce is currently chairman of Arkuda Therapeutics, AvroBio, Hotspot Therapeutics, Kymera Therapeutics, Nimbus Therapeutics, Quench Bio, and Unum Therapeutics, and also serves on the boards of Lysosomal Therapeutics and Magenta Therapeutics. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and a number of other ventures. Bruce serves as an advisor in various capacities to UCB, Takeda, and the Gates Foundation. He also serves on the boards of the National Venture Capital Association, the Pennsylvania State Research Foundation, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at, which is syndicated on Forbes. Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a DPhil (PhD) in molecular immunology from Oxford University. He enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.